Genentech withdraws Raptiva
Pharma Compliance Alert, April 22, 2009
Genentech is voluntarily withdrawing its psoriasis drug Raptiva from the U.S. market because of the drug’s association with an increased risk of progressive multifocal leukoencephalopathy (PML), a rare and usually fatal disease of the central nervous system, the company announced.
Genentech estimates 2,000 patients in the U.S. take Raptiva for chronic plaque psoriasis and approximately 46,000 patients worldwide have been treated with Raptiva since 2003. Three patients receiving Raptiva were diagnosed with PML and a fourth developed progressive neurologic symptoms and died of an unknown cause.
Genentech advised physicians to stop writing Raptiva prescriptions for new patients and to work with patients currently taking the drug to find an alternative treatment. Raptiva will not be available after June 8.
Related Products
-
ePharm5 InDepth
EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...
-
Critical Test Results Troubleshooter:
Improve your hospital's system of critical test results (CTR) communication with this handy book and CD-ROM set. It provides...
-
Occurrence Reporting:
Take advantage of the information occurrence reports provide and make sustainable enhancements at your facility. Expert...
-
Big Pharma Performance Before, During and Beyond the Global Recession
This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the recent global...
-
Creating a Just Culture: A Nurse Leader's Guide
This practical resource explains the process of creating and sustaining a just culture in which staff members are encouraged...
Most Popular
- Articles
-
- HIPAA Q&A: Flu shot requirement for hospital employees
- HealthDataInsights posts new issues for medical necessity claims
- Running an effective peer review committee meeting
- Sneak Peek: Effort underway to establish caseload benchmarks
- New FAQ posted on storing laryngoscope blades
- Q&A: Incidental disclosures and patient privacy
- Tip: Perform your own internal investigation prior to government audit
- What does case-mix index mean to you?
- HIPAA 5010 deadline extended, but threat remains, says AMA
- HHS task force: Consider privacy, security with text messages
- E-mailed
-
- Running an effective peer review committee meeting
- HIPAA Q&A: Flu shot requirement for hospital employees
- What does case-mix index mean to you?
- HHS task force: Consider privacy, security with text messages
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Tip: Correctly code bilateral pain management procedures
- 2012 CPT code changes for ASCs: Shoulder and knee scopes and pain management
- COT basics to best
- Documentation and coding for toxic metabolic encephalopathy
- Guidance and tact key to compliant, effective physician queries
- Searched